Improvements to tiny body-on-a-chip devices could lead to next-generation pre-clinical testing of drug toxicity
Researchers at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) in Japan have designed a small ‘body-on-a-chip’ device that can test the side effects of drugs s on human cells. The device solves some issues with current, similar microfluidic devices and offers promise for the next generation of pre-clinical drug tests.
The Integrated Heart/Cancer on a Chip (iHCC) was used to test the toxicity of the anti-cancer drug doxorubicin on heart cells. The researchers, led by iCeMS’s Ken-ichiro Kamei, found that, while the drug itself was not toxic to heart cells, a metabolite of the drug resulting from its interaction with cancer cells was.
The device is smaller than a microscope glass slide. It contains six tiny chambers; every two are connected by microchannels with a series of port inlets and valves. A pneumatic pump controls movement of fluid through the channels. Every two chambers and their separate microchannel system constitute one test bed. Three test beds in the device allow for the introduction of minor changes in each bed to simultaneously compare results.
The team first tested doxorubicin’s effects on heart cells and liver cancer cells cultured separately in small wells. The drug had the expected anti-cancer effect on the cancer cells without causing damage to the heart cells.
They then ran the test using the iHCC device. Heart cells were placed in one chamber while liver cancer cells were placed in the other. Doxorubicin was introduced into a cell culture medium circulating through a closed-loop system of microchannels that connects the two chambers, mimicking the blood’s circulatory system. In this way, the drug flows unidirectionally in a continuous loop through both chambers.
The team found signs of toxicity in both cancer and heart cells. They hypothesized that a compound, doxorubicinol, which is a metabolic byproduct of doxorubicin interacting with cancer cells, was causing the toxic effect.
To test this, they added doxorubicinol to heart cells and liver cancer cells cultured separately in small wells. It was toxic to the heart cells but not to the cancer cells.
When doxorubicin alone is added to the liver cancer cells, the amount of doxorubicinol produced is too small to be toxic to the heart cells. The team believes this is because the amount of cell culture medium needed for the well-based tests dilutes the metabolite.
In contrast, when doxorubicin is introduced into the iHCC, the metabolite is not diluted when moving through the microchannel circulation system because a smaller volume of cell culture is needed. As a result, the drug does have a toxic effect on the heart cells via its metabolite.
The device requires further improvements, but the study demonstrates how this design concept could be used to investigate the toxic side effects of anti-cancer drugs on heart cells well before expensive clinical trials. The study was published in the journal Royal Society of Chemistry Advances.
Learn more: Next-generation drug testing on chips
The Latest on: Body-on-a-chip
- Hesperos: A CRO For Body-On-A-Chip Enthusiastson October 6, 2019 at 5:00 pm
Recent advances (DOI: 10.1021/acs.analchem.8b05293) in body-on-a-chip systems include a trend toward the use of plastic materials with lower adsorption and absorption rates of drugs and development of ...
- Body-on-a-Chip Device Predicts Cancer Drug Responseson September 26, 2019 at 6:03 am
These body-on-a-chip (BOC) devices place each tissue type in its own pea-sized chamber and connect them via fluid-filled microchannels into living, integrated biological systems on a laboratory plate.
- Body-on-a-chip for anticancer drug testingon July 4, 2019 at 1:07 am
All prices are NET prices. VAT will be added later in the checkout. Rent or Buy article Get time limited or full article access on ReadCube.
- Body-on-a-chip Model Tests Efficacy and Toxicity of Cancer Drugson June 20, 2019 at 10:17 am
"Body-on-a-chip" model could measure drug's efficacy and toxicity, for both target cells and other organs like the heart and liver. This can revolutionize biomedical research and personalized medicine ...
- This body-on-a-chip mimics how organs and cancer cells react to drugson June 19, 2019 at 11:02 am
A new body-on-a-chip system could provide a more holistic view of drug effects than other devices of its kind. “Until now, to be able to [measure] efficacy and toxicity in the same system, you had to ...
- Drug testing could get a boost from MIT’s ‘body on a chip’on March 19, 2018 at 5:05 pm
Others, however, can have serious consequences. Now a new technology called a microphysiological system — or “body on a chip” — may help identify potential problems faster. Developed by engineers at ...
- MIT builds 'body-on-a-chip' device that stores 10 artificial organson March 15, 2018 at 5:26 pm
The paperback-sized device, called a 'body-on-a-chip,' can hold up to 10 artificial 'human' organs. Similarly, researchers have created an 'organ-on-a-chip,' 'menstrual-cycle-on-a-chip' and a ...
- ‘Body-on-a-chip’ Helps in Testing New Drugs Quicklyon October 9, 2017 at 12:46 pm
Micro-sized 3D organs such as micro hearts, lungs, and livers were build to test the effects of new drugs on the body "Body-on-a-chip" system can predict the effects of drugs, chemicals and biological ...
- Researchers Use 3D Printing to Create Organoids for Drug Testing in Monitored Body-On-A-Chip Systemon October 8, 2017 at 9:25 am
These micro 3D organs, or organoids, are then combined in a monitored system, known as a body-on-a-chip, so researchers can replicate how the human body as a whole responds to medications. In addition ...
- Scientists develop 'body-on- a-chip' system to accelerate testing of new drugson October 5, 2017 at 9:40 am
Using the same expertise they've employed to build new organs for patients, scientists at Wake Forest Institute for Regenerative Medicine and colleagues have engineered micro hearts, lungs and livers ...
via Google News and Bing News